However this strategy may not be generally applied to cetuximab as NRG1 expression was markedly lower in colorectal cancer (CRC), another tumor type where cetuximab is an approved therapy and where EGFR signaling has been implicated. This evidence concerns the gene NRG1 and colorectal cancer.